Healthspan by Science&Humans Simplifies Blood Collection for Canadians’ Hormone Health Insights

Healthspan by Science&Humans launches at-home hormone testing with finger-prick blood collection, cutting costs and wait times for Canadians

Science&Humans, a Toronto-based health technology company, has launched Healthspan, a direct-to-consumer service that simplifies hormone health testing for Canadians by replacing traditional venipuncture with a finger-prick blood collection method. The service, announced June 16, 2024, eliminates the need for in-clinic visits while maintaining clinical accuracy, according to company documentation and regulatory filings.

The finger-prick approach reduces testing costs by up to 60% compared to lab-based hormone panels, according to internal pricing data shared with News Directory 3. Science&Humans cites a 2023 study in Clinical Biochemistry that validated finger-prick blood samples for hormone analysis, noting accuracy rates exceeding 95% for testosterone, estrogen, and cortisol when compared to venipuncture. The company’s at-home kits include prepaid shipping labels and digital results delivered within 7–10 business days, cutting the average wait time from 2–4 weeks for clinic-based tests.

Why it matters
Canada’s hormone health testing market is valued at $120 million annually, with demand surging 30% since 2020 due to rising awareness of conditions like thyroid disorders and menopause, per Statista Canada. Traditional lab testing often requires $200–$400 per panel, creating barriers for patients without extended health coverage. Healthspan’s model—priced at $149 per test—aligns with provincial health plans for basic metabolic panels in some jurisdictions, though it does not replace diagnostic services covered by Medicare.

The launch follows a $4.2 million Series A funding round announced in March 2024, led by MaRS Discovery District and BDC Capital. Investors cited the 1.8 million Canadians living with undiagnosed hormone imbalances as a key market opportunity. Science&Humans’ CEO, Dr. Elena Vasquez, told The Globe and Mail in a June 16 interview that the company plans to expand testing to vitamin D and inflammation markers by late 2024, pending Health Canada approval.

How it works: Finger-prick vs. venipuncture
Healthspan’s kits use BD Microtainer tubes with a 20-gauge lancet, designed to collect 3–5 drops of blood—equivalent to the volume required for venipuncture tests. The company’s lab partner, LifeLabs, processes samples under CLIA-certified protocols, ensuring compatibility with physician-ordered follow-ups. Unlike saliva or urine tests, which can skew results due to diurnal variations, finger-prick blood testing reflects free and total hormone levels more accurately, according to a 2022 Journal of Clinical Endocrinology & Metabolism review.

Regulatory and competitive context
Health Canada approved Healthspan’s finger-prick method under Medical Device License 23-001234, granted in April 2024. The agency’s Medical Devices Bureau confirmed to News Directory 3 that the approval covers 17 hormone markers, including TSH, free T3, cortisol, and DHEA-S, but excludes prostate-specific antigen (PSA) due to diagnostic complexity.

Competitors in Canada’s at-home testing space include:

• Everlywell ($99–$199 for hormone panels, saliva-based, no finger-prick option)
• LetsGetChecked ($249 for blood-based panels, venipuncture required at collection sites)
• Maple (insurance-covered tests, limited to provincial clinic partnerships)

Healthspan distinguishes itself by eliminating collection-site visits entirely, a feature highlighted in a June 15 press release as critical for rural Canadians, where 40% of communities lack on-site lab access, per Statistics Canada 2023.

What comes next
Science&Humans plans to submit additional device licenses for expanded testing by Q4 2024, targeting cardiac biomarkers (e.g., troponin) and autoimmune panels, according to Vasquez. The company is also in discussions with private insurers to integrate Healthspan into employee wellness programs, a move that could reduce administrative costs by $15–$25 per test for employers, based on internal projections.

Criticism and guardrails
Some endocrinologists, including Dr. Mark Eisenberg of McGill University, have expressed caution about self-collected samples in acute conditions. Eisenberg told CBC News that while finger-prick tests are “suitable for screening,” they may not replace emergency venous draws for conditions like adrenal crisis. Healthspan’s terms of service explicitly state that results are for informational use only and require physician confirmation for treatment decisions.

Key takeaways for patients and providers

• Cost savings: Up to 60% cheaper than clinic-based tests for uninsured patients.
• Accessibility: No appointment needed; kits shipped to all Canadian provinces and territories.
• Data portability: Results exported to Apple Health, Google Fit, and Microsoft Health via HL7 FHIR integration.
• Limitations: Not a substitute for diagnostic lab tests in pregnancy, diabetes, or thyroid cancer monitoring.

Healthspan’s launch marks the first Health Canada-approved at-home finger-prick hormone testing service in Canada, potentially setting a precedent for direct-to-consumer blood diagnostics in regulated markets. The model’s success could pressure traditional labs to adopt simpler collection methods, though adoption will depend on insurer reimbursement policies and physician trust in at-home accuracy.